Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant
Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)
Has a Karnofsky Performance Status (KPS) of ≥60%
You may not be if
Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study
Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis
Has a New York Heart Association (NYHA) heart failure classification \>2
Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 upper limit of normal (ULN)
Has total bilirubin \>1.5 ULN
Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m\^2
Has other known causes of sensorimotor or autonomic neuropathy
Clareo Health | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
